{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:29:17Z","timestamp":1780374557485,"version":"3.54.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Schizophr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study reports a medium-term follow-up of a randomised, double-blind, placebo-controlled trial of omega-3 polyunsaturated fatty acids (PUFA) in ultra-high risk for psychosis (UHR) patients. Primary outcomes of interest were transition to psychosis and symptomatic and functional outcome. A secondary aim was to investigate clinical predictors of medium-term outcome. Three hundred four UHR participants were recruited across 10 specialised early psychosis services in Australia, Asia, and Europe. The intervention consisted of 1.4\u2009g\/daily of omega-3 PUFA or placebo, plus up to 20 sessions of cognitive-behavioural case management (CBCM), over the 6-month study period, with participants receiving further CBCM sessions on basis of need between months 6\u201312. Mean time to follow-up was 3.4 (median\u2009=\u20093.3; SD\u2009=\u20090.9) years. There was a modest increase in transitions between 12-month and medium-term follow-up (11\u201313%) and substantial improvement in symptoms and functioning between baseline and follow-up, with no differences between the treatment groups. Most improvement had been achieved by end of the intervention. 55% of the sample received mental health treatment between end of intervention and follow-up. Omega-3 PUFA did not provide additional benefits to good quality psychosocial intervention over the medium term. Although most improvement had been achieved by end of intervention the substantial rates of post-intervention mental health service use indicate longer-term clinical need in UHR patients. The post-intervention phase treatment or the longer-term effect of CBCM, or a combination of the two, may have contributed to maintaining the gains achieved during the intervention phase and prevented significant deterioration after this time.<\/jats:p>","DOI":"10.1038\/s41537-018-0052-x","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T10:02:49Z","timestamp":1529402569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders\u2014medium-term follow-up and clinical course"],"prefix":"10.1038","volume":"4","author":[{"given":"B.","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. P.","family":"Amminger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. P.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Markulev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mossaheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schl\u00f6gelhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Smesny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. B.","family":"Hickie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Y. H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. H.","family":"Nieman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nordentoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Riecher-R\u00f6ssler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. R.","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. D.","family":"McGorry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"key":"52_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/schbul\/22.2.283","volume":"22","author":"AR Yung","year":"1996","unstructured":"Yung, A. R. et al. Monitoring and care of young people at incipient risk of psychosis. Schizophr. Bull. 22, 283\u2013303 (1996).","journal-title":"Schizophr. Bull."},{"key":"52_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/schbul\/22.2.353","volume":"22","author":"AR Yung","year":"1996","unstructured":"Yung, A. R. & McGorry, P. D. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. 22, 353\u2013370 (1996).","journal-title":"Schizophr. Bull."},{"key":"52_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0920-9964(02)00167-6","volume":"60","author":"AR Yung","year":"2003","unstructured":"Yung, A. R. et al. Psychosis prediction: 12-month follow up of a high-risk (\u201cprodromal\u201d) group. Schizophr. Res. 60, 21\u201332 (2003).","journal-title":"Schizophr. Res."},{"key":"52_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamapsychiatry.2013.269","volume":"70","author":"P Fusar-Poli","year":"2013","unstructured":"Fusar-Poli, P. et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 70, 107\u2013120 (2013).","journal-title":"JAMA Psychiatry"},{"key":"52_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.schres.2013.07.004","volume":"149","author":"M van der Gaag","year":"2013","unstructured":"van der Gaag, M. et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr. Res. 149, 56\u201362 (2013).","journal-title":"Schizophr. Res."},{"key":"52_CR6","doi-asserted-by":"publisher","first-page":"f185","DOI":"10.1136\/bmj.f185","volume":"346","author":"MR Stafford","year":"2013","unstructured":"Stafford, M. R., Jackson, H., Mayo-Wilson, E., Morrison, A. P. & Kendall, T. Early interventions to prevent psychosis: systematic review and meta-analysis. Br. Med. J. 346, f185 (2013).","journal-title":"Br. Med. J."},{"key":"52_CR7","first-page":"1","volume":"44","author":"P Hutton","year":"2013","unstructured":"Hutton, P. & Taylor, P. J. Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. Psychol. Med. 44, 1\u201320 (2013).","journal-title":"Psychol. Med."},{"key":"52_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamapsychiatry.2015.2868","volume":"73","author":"P McGorry","year":"2016","unstructured":"McGorry, P. & Nelson, B. Why we need a transdiagnostic staging approach to emerging psychopathology, early diagnosis, and treatment. JAMA Psychiatry 73, 1\u20132 (2016).","journal-title":"JAMA Psychiatry"},{"key":"52_CR9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1080\/j.1440-1614.2006.01860.x","volume":"40","author":"PD McGorry","year":"2006","unstructured":"McGorry, P. D., Hickie, I. B., Yung, A. R., Pantelis, C. & Jackson, H. J. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust. N. Z. J. Psychiatry 40, 616\u2013622 (2006).","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"52_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.schres.2010.03.016","volume":"120","author":"PD McGorry","year":"2010","unstructured":"McGorry, P. D. Risk syndromes, clinical staging and DSM V: new diagnostic infrastructure for early intervention in psychiatry. Schizophr. Res. 120, 49\u201353 (2010).","journal-title":"Schizophr. Res."},{"key":"52_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/wps.20080","volume":"12","author":"PD McGorry","year":"2013","unstructured":"McGorry, P. D. The next stage for diagnosis: validity through utility. World Psychiatry 12, 213\u2013215 (2013).","journal-title":"World Psychiatry"},{"key":"52_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.biopsych.2013.07.004","volume":"74","author":"PD McGorry","year":"2013","unstructured":"McGorry, P. D. Early clinical phenotypes, clinical staging, and strategic biomarker research: building blocks for personalized psychiatry. Biol. Psychiatry 74, 394\u2013395 (2013).","journal-title":"Biol. Psychiatry"},{"key":"52_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.schres.2010.10.015","volume":"125","author":"J Addington","year":"2011","unstructured":"Addington, J. et al. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr. Res. 125, 54\u201361 (2011).","journal-title":"Schizophr. Res."},{"key":"52_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1192\/bjp.185.4.291","volume":"185","author":"AP Morrison","year":"2004","unstructured":"Morrison, A. P. et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br. J. Psychiatry 185, 291\u2013297 (2004).","journal-title":"Br. J. Psychiatry"},{"key":"52_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/schbul\/sbl042","volume":"33","author":"AP Morrison","year":"2007","unstructured":"Morrison, A. P. et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr. Bull. 33, 682\u2013687 (2007).","journal-title":"Schizophr. Bull."},{"key":"52_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2233","volume":"344","author":"AP Morrison","year":"2012","unstructured":"Morrison, A. P. et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. Br. Med. J. 344, e2233 (2012).","journal-title":"Br. Med. J."},{"key":"52_CR17","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/schbul\/sbs105","volume":"38","author":"M van der Gaag","year":"2012","unstructured":"van der Gaag, M. et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr. Bull. 38, 1180\u20131188 (2012).","journal-title":"Schizophr. Bull."},{"key":"52_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/schbul\/sbw018","volume":"42","author":"HK Ising","year":"2016","unstructured":"Ising, H. K. et al. Four-year follow-up of cognitive behavioral therapy in persons at ultra-high risk for developing psychosis: the Dutch early detection intervention evaluation (EDIE-NL) trial. Schizophr. Bull. 42, 1243\u20131252 (2016).","journal-title":"Schizophr. Bull."},{"key":"52_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.schres.2016.08.008","volume":"176","author":"HJ Stain","year":"2016","unstructured":"Stain, H. J. et al. A randomised controlled trial of cognitive behaviour therapy versus non-directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophr. Res. 176, 212\u2013219 (2016).","journal-title":"Schizophr. Res."},{"key":"52_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/archgenpsychiatry.2009.192","volume":"67","author":"GP Amminger","year":"2010","unstructured":"Amminger, G. P. et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 67, 146\u2013154 (2010).","journal-title":"Arch. Gen. Psychiatry"},{"key":"52_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8934","volume":"6","author":"GP Amminger","year":"2015","unstructured":"Amminger, G. P., Schafer, M. R., Schlogelhofer, M., Klier, C. M. & McGorry, P. D. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat. Commun. 6, 7934 (2015).","journal-title":"Nat. Commun."},{"key":"52_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jamapsychiatry.2016.2902","volume":"74","author":"PD McGorry","year":"2017","unstructured":"McGorry, P. D. et al. Effect of omega-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry 74, 19\u201327 (2017).","journal-title":"JAMA Psychiatry"},{"key":"52_CR23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/eip.12260","volume":"11","author":"C Markulev","year":"2015","unstructured":"Markulev, C. et al. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Early Interv. Psychiatry 11, 418\u2013428 (2015).","journal-title":"Early Interv. Psychiatry"},{"key":"52_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.schres.2007.05.018","volume":"96","author":"LJ Phillips","year":"2007","unstructured":"Phillips, L. J. et al. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr. Res. 96, 25\u201333 (2007).","journal-title":"Schizophr. Res."},{"key":"52_CR25","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1176\/ajp.2006.163.5.790","volume":"163","author":"TH McGlashan","year":"2006","unstructured":"McGlashan, T. H. et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 163, 790\u2013799 (2006).","journal-title":"Am. J. Psychiatry"},{"key":"52_CR26","first-page":"146","volume":"5","author":"TH McGlashan","year":"2004","unstructured":"McGlashan, T. H. et al. Olanzapine for treatment of the schizophrenia prodrome: 2 year results of a randomized placebo-controlled study. World J. Biol. Psychiatry 5, 146 (2004).","journal-title":"World J. Biol. Psychiatry"},{"key":"52_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1192\/bjp.bp.109.066357","volume":"200","author":"A Bechdolf","year":"2012","unstructured":"Bechdolf, A. et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br. J. Psychiatry 200, 22\u201329 (2012).","journal-title":"Br. J. Psychiatry"},{"key":"52_CR28","doi-asserted-by":"publisher","unstructured":"Nelson, B. et al. Staged treatment in early psychosis: a sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients. Early Interv. Psychiatry. https:\/\/doi.org\/10.1111\/eip.12459 (2017).","DOI":"10.1111\/eip.12459"},{"key":"52_CR29","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/S0140-6736(07)61732-2","volume":"370","author":"P Fusar-Poli","year":"2007","unstructured":"Fusar-Poli, P., Valmaggia, L. & McGuire, P. Can antidepressants prevent psychosis? Lancet 370, 1746\u20131748 (2007).","journal-title":"Lancet"},{"key":"52_CR30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/070674370705200502","volume":"52","author":"E Cantor-Graae","year":"2007","unstructured":"Cantor-Graae, E. The contribution of social factors to the development of schizophrenia: a review of recent findings. Can. J. Psychiatry 52, 277\u2013286 (2007).","journal-title":"Can. J. Psychiatry"},{"key":"52_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/00006842-199909000-00004","volume":"61","author":"G Chen","year":"1999","unstructured":"Chen, G. et al. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom. Med. 61, 599\u2013617 (1999).","journal-title":"Psychosom. Med."},{"key":"52_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0306-4522(00)00390-0","volume":"100","author":"AT Michael-Titus","year":"2000","unstructured":"Michael-Titus, A. T., Bains, S., Jeetle, J. & Whelpton, R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex\u2014a possible mechanism of neuroprotection in major depression? Neuroscience 100, 681\u2013684 (2000).","journal-title":"Neuroscience"},{"key":"52_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/sj.bjp.0704230","volume":"134","author":"V Sanchez","year":"2001","unstructured":"Sanchez, V. et al. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA (\u2018ecstasy\u2019)-induced degeneration of 5-HT nerve endings in rat brain. Br. J. Pharmacol. 134, 46\u201357 (2001).","journal-title":"Br. J. Pharmacol."},{"key":"52_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.schres.2016.04.040","volume":"174","author":"B Nelson","year":"2016","unstructured":"Nelson, B. et al. Further examination of the reducing transition rate in ultra high risk for psychosis samples: the possible role of earlier intervention. Schizophr. Res. 174, 43\u201349 (2016).","journal-title":"Schizophr. Res."},{"key":"52_CR35","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jamapsychiatry.2016.2707","volume":"73","author":"P Fusar-Poli","year":"2016","unstructured":"Fusar-Poli, P. et al. Deconstructing pretest risk enrichment to optimize prediction of psychosis in individuals at clinical high risk. JAMA Psychiatry 73, 1260\u20131267 (2016).","journal-title":"JAMA Psychiatry"},{"key":"52_CR36","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.schres.2017.06.015","volume":"192","author":"P Fusar-Poli","year":"2017","unstructured":"Fusar-Poli, P. et al. Why transition risk to psychosis is not declining at the OASIS ultra high risk service: the hidden role of stable pretest risk enrichment. Schizophr. Res. 192, 385\u2013390 (2017).","journal-title":"Schizophr. Res."},{"key":"52_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/eip.12105","volume":"9","author":"S Wiltink","year":"2015","unstructured":"Wiltink, S., Velthorst, E., Nelson, B., McGorry, P. M. & Yung, A. R. Declining transition rates to psychosis: the contribution of potential changes in referral pathways to an ultra-high-risk service. Early Interv. Psychiatry 9, 200\u2013206 (2015).","journal-title":"Early Interv. Psychiatry"},{"key":"52_CR38","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.schres.2015.11.026","volume":"170","author":"JA Hartmann","year":"2016","unstructured":"Hartmann, J. A. et al. Declining transition rates to psychotic disorder in \u201cultra-high risk\u201d clients: investigation of a dilution effect. Schizophr. Res. 170, 130\u2013136 (2016).","journal-title":"Schizophr. Res."},{"key":"52_CR39","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/jamapsychiatry.2013.1270","volume":"70","author":"B Nelson","year":"2013","unstructured":"Nelson, B. et al. Long-term follow-up of a group at ultra high risk (\u201cprodromal\u201d) for psychosis: the PACE 400 study. JAMA Psychiatry 70, 793\u2013802 (2013).","journal-title":"JAMA Psychiatry"},{"key":"52_CR40","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1176\/appi.ajp.2016.15070890","volume":"173","author":"TD Cannon","year":"2016","unstructured":"Cannon, T. D. et al. An individualized risk calculator for research in prodromal psychosis. Am. J. Psychiatry 173, 980\u2013988 (2016).","journal-title":"Am. J. Psychiatry"},{"key":"52_CR41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.schres.2004.04.006","volume":"71","author":"O Mason","year":"2004","unstructured":"Mason, O. et al. Risk factors for transition to first episode psychosis among individuals with \u2018at-risk mental states\u2019. Schizophr. Res. 71, 227\u2013237 (2004).","journal-title":"Schizophr. Res."},{"key":"52_CR42","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/j.1440-1614.2005.01714.x","volume":"39","author":"AR Yung","year":"2005","unstructured":"Yung, A. R. et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust. N. Z. J. Psychiatry 39, 964\u2013971 (2005).","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"52_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/schbul\/sbj007","volume":"32","author":"N Haroun","year":"2006","unstructured":"Haroun, N., Dunn, L., Haroun, A. & Cadenhead, K. S. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr. Bull. 32, 166\u2013178 (2006).","journal-title":"Schizophr. Bull."},{"key":"52_CR44","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1017\/S0033291799001841","volume":"30","author":"RV Bijl","year":"2000","unstructured":"Bijl, R. V. & Ravelli, A. Current and residual functional disability associated with psychopathology: findings from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Psychol. Med. 30, 657\u2013668 (2000).","journal-title":"Psychol. Med."},{"key":"52_CR45","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1001\/archgenpsychiatry.2011.1578","volume":"69","author":"H Joffe","year":"2012","unstructured":"Joffe, H. et al. Lifetime history of depression and anxiety disorders as a predictor of quality of life in midlife women in the absence of current illness episodes. Arch. Gen. Psychiatry 69, 484\u2013492 (2012).","journal-title":"Arch. Gen. Psychiatry"},{"key":"52_CR46","unstructured":"Group, T. P. M. W. The PACE Clinic Manual: A Treatment Approach for Young People at Ultra High Risk of Psychosis (Orygen Youth Health, Melbourne, 2012)."},{"key":"52_CR47","doi-asserted-by":"publisher","unstructured":"Yuen, H. P., Mackinnon, A. & Nelson, B. A method for analysing transition to psychosis: joint modelling of time-to-event outcome with time-dependent predictors. Int. J. Methods Psychiatr. Res. https:\/\/doi.org\/10.1002\/mpr.1588 (2017).","DOI":"10.1002\/mpr.1588"},{"key":"52_CR48","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jamapsychiatry.2017.0001","volume":"74","author":"B Nelson","year":"2017","unstructured":"Nelson, B., McGorry, P. D., Wichers, M., Wigman, J. T. W. & Hartmann, J. Moving from static to dynamic models of the onset of mental disorder. JAMA Psychiatry 74, 528\u2013534 (2017).","journal-title":"JAMA Psychiatry"},{"key":"52_CR49","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1176\/appi.ajp.2014.13030418","volume":"172","author":"A Lin","year":"2015","unstructured":"Lin, A. et al. Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. Am. J. Psychiatry 172, 249\u2013258 (2015).","journal-title":"Am. J. Psychiatry"},{"key":"52_CR50","doi-asserted-by":"publisher","unstructured":"Woods, S. W. E. A. Lack of diagnostic pluripotentiality in patients at clinical high risk for psychosis: speci city of comorbidity persistence and search for pluripotential subgroups. Schizophr. Bull. https:\/\/doi.org\/10.1093\/schbul\/sbx138 (2017).","DOI":"10.1093\/schbul\/sbx138"},{"key":"52_CR51","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1097\/01.nmd.0000243761.52104.91","volume":"194","author":"K Allott","year":"2006","unstructured":"Allott, K., Chanen, A. & Yuen, H. P. Attrition bias in longitudinal research involving adolescent psychiatric outpatients. J. Nerv. Ment. Dis. 194, 958\u2013961 (2006).","journal-title":"J. Nerv. Ment. Dis."},{"key":"52_CR52","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1159\/000477551","volume":"86","author":"JA Hartmann","year":"2017","unstructured":"Hartmann, J. A. et al. Opening the black box of cognitive-behavioural case management in clients with ultra-high risk for psychosis. Psychother. Psychosom. 86, 292\u2013299 (2017).","journal-title":"Psychother. Psychosom."},{"key":"52_CR53","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical, A.","year":"2013","unstructured":"World Medical, A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J. Am. Med. Assoc. 310, 2191\u20132194 (2013).","journal-title":"J. Am. Med. Assoc."},{"key":"52_CR54","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall, J. E. & Gorham, D. R. The brief psychiatric rating scale. Psychol. Rep. 10, 799\u2013812 (1962).","journal-title":"Psychol. Rep."},{"key":"52_CR55","doi-asserted-by":"crossref","unstructured":"Andreasen, N. C. Scale for the Assessment of Negative Symptoms (SANS) (University of Iowa, Iowa City, 1983).","DOI":"10.1037\/t12696-000"},{"key":"52_CR56","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery, S. A. & Asberg, M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382\u2013389 (1979).","journal-title":"Br. J. Psychiatry"},{"key":"52_CR57","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"RC Young","year":"1978","unstructured":"Young, R. C., Biggs, J. T., Ziegler, V. E. & Meyer, D. A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133, 429\u2013435 (1978).","journal-title":"Br. J. Psychiatry"},{"key":"52_CR58","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1176\/ajp.149.8.1119-a","volume":"149","author":"HH Goldman","year":"1992","unstructured":"Goldman, H. H., Skodol, A. E. & Lave, T. R. Revising axis V for DSM-IV: a review of measures of social functioning. Am. J. Psychiatry 149, 1148\u20131156 (1992).","journal-title":"Am. J. Psychiatry"},{"key":"52_CR59","unstructured":"Auther, A., Smith, C. & Cornblatt, B. Global Functioning: Social Scale (GF: Social) (Zucker-Hillside Hospital, New York, 2006)."},{"key":"52_CR60","volume-title":"Global Functioning: Role Scale (GF: Role)","author":"TA Niendam","year":"2006","unstructured":"Niendam, T. A., Bearden, C. E., Johnson, J. K. & TD, C. Global Functioning: Role Scale (GF: Role). (University of California, Los Angeles, 2006)."}],"container-title":["npj Schizophrenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41537-018-0052-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-018-0052-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-018-0052-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T23:15:26Z","timestamp":1671578126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41537-018-0052-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1038\/s41537-018-0052-x","relation":{},"ISSN":["2334-265X"],"issn-type":[{"value":"2334-265X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,25]]},"assertion":[{"value":"19 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. McGorry reported receiving grant funding from National Alliance for Research on Schizophrenia and Depression and unrestricted research funding from AstraZeneca, Eli Lilly, Janssen-Cilag, Pfizer, and Novartis, as well as honoraria for educational activities with AstraZeneca, Eli Lilly, Janssen-Cilag, Pfizer, Bristol-Myers Squibb, Roche, and the Lundbeck Institute. Drs. Nelson, Hickie, Yung, and Amminger have received National Health and Medical Research Council (NHMRC) funding. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}